Kalohexis Adds Seasoned Biotech Executive to Board Amid Growth Push
Event summary
- Kalohexis appoints Thomas Forest Farb-Horch to its Board of Directors on September 22, 2026.
- Farb-Horch brings over three decades of experience in life sciences, AI, and capital markets.
- He will also chair the Board's Audit Committee.
- Farb-Horch is currently CEO of Thrive Bioscience and Managing Director at Cappello Group.
- Kalohexis focuses on metabolic diseases, with lead programs targeting obesity and cancer cachexia.
The big picture
Kalohexis' appointment of Farb-Horch underscores its push to leverage AI and data science in drug discovery, a trend gaining traction in biotech. His experience in scaling companies and navigating public transactions could be pivotal as Kalohexis advances its clinical programs and seeks to address significant unmet needs in metabolic diseases. The move also highlights the increasing intersection of life sciences and technology, particularly in targeting complex conditions like obesity and cancer cachexia.
What we're watching
- Clinical Progress
- How Kalohexis advances its 710GO and mifomelatide programs through clinical trials.
- AI Integration
- Whether Farb-Horch's expertise will accelerate Kalohexis' use of AI tools in drug development.
- Growth Strategy
- The pace at which Kalohexis scales its organization and pipeline amid its next growth phase.
Related topics